Guidelines

Sexual and Reproductive Health

Want to read the guideline in your own time? Download the PDF

Download full guideline

Looking for a quick overview? Check the pocket guidelines.

Download pocket guidelines

For the 2026 Sexual and Reproductive Health Guidelines new and relevant evidence was identified, collated and appraised through a structured assessment of the literature for the Hypogonadism, Disorders of Ejaculation, Penile Curvature and Priapism sections of the Guidelines. This resulted in the inclusion of 116 updated studies across the Guidelines. Key changes include:

  • Significant changes to the supporting text throughout Section 3. Hypogonadism.
  • Significant revision of 3.5.4 Prostate cancer (PCa).
  • The relocation of two recommendations to section 3.5.4 addressing Prostate Cancer (PCa) topics because their conceptual framework and clinical implications were more directly aligned with PCa-related management strategies and outcomes.
  • The reorganisation of the recommendations in section 5.6.12 Summary of evidence and recommendations for treatment of erectile dysfunction (ED), so that they flow in a more logical manner.
  • Full update and revision of the supporting text and references throughout Section 6 Disorders of Ejaculation.
  • Significant revision of 8.2.1 Epidemiology in the Penile Curvature section.
  • Significant revision of 8.2.3.a Conservative treatment in the Penile Curvature section.
  • Significant revision of 8.2.3.a.1 Oral treatment in the Penile Curvature section.
  • Significant revision of 8.2.3.a.4 Other treatments in the Penile Curvature section.
  • Significant revision of 8.2.3.b Surgical treatment in the Penile Curvature section.
  • Significant revision of section 10.1 Ischaemic (Low-Flow or Veno-Occlusive) Priapism
  • Significant revision of 10.1.3.b Surgical management- second-line treatments in the Priapism section.
  • Significant revision of 10.2 Priapism in Special Situations

Updates/modifications to the following recommendations:

  • Summary of evidence and recommendations for the diagnostic evaluation and screening of LOH
  • 3.4.2.f Summary of evidence and recommendations for testosterone therapy outcome
  • 3.5.9 Summary of evidence and recommendations on safety and monitoring in
  • 8.2.3.a.4 Summary of evidence and recommendations for conservative treatment of Peyronie’s disease
  • 8.2.3.b.4 Summary of evidence and recommendations for surgical treatment of
  • 10.1.2.e Summary of evidence and recommendations for the diagnosis of
  • 10.1.4 Summary of evidence and recommendations for treatment of ischaemic priapism